Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Clin Infect Dis. 2021 Sep 15;73(6):e1372-e1375. doi: 10.1093/cid/ciab302.
The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.
尚未报道过抗人 CD38 单克隆抗体（达雷妥尤单抗）治疗后乙型肝炎表面抗原（HBsAg）阴性多发性骨髓瘤患者乙型肝炎病毒（HBV）再激活的风险。在 93 例接受达雷妥尤单抗治疗的患者中，有 6 例（6.5%）患者发生了再激活，其中 1 例发生肝衰竭。这是首次报道抗人 CD38 单克隆抗体治疗后乙型肝炎病毒再激活风险较大。
